Valuation: Mymetics Corporation

Market Cap 439K 380K 354K 325K 612K 41.77M 621K 4.16M 1.63M 20.93M 1.65M 1.61M 69.21M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.41M 58.25M 53.47M 101M 6.87B 102M 683M 268M 3.44B 271M 265M 11.38B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
29.2
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-82.22% 45
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+2.72%+3.41%-16.11%-7.96% 23.53B
+10.83%+18.38%+56.20%+6.03% 23.99B
+6.50%+7.56%+44.65%-21.73% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+33.87%+693.38% 16.44B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +8.01%+10.51%+106,705.16%+177.99% 26.36B
Weighted average by Cap. +4.36%+13.10%+50.42%+167.88%

Financials

2021 2022
Net sales 430K 372K 347K 319K 599K 40.94M 608K 4.07M 1.6M 20.51M 1.61M 1.58M 67.83M 1.03M 890K 830K 762K 1.43M 97.87M 1.45M 9.74M 3.82M 49.03M 3.86M 3.78M 162M
Net income -4.73M -4.09M -3.82M -3.51M -6.59M -450M -6.69M -44.82M -17.57M -226M -17.76M -17.37M -746M -4.8M -4.16M -3.88M -3.56M -6.7M -457M -6.8M -45.53M -17.85M -229M -18.04M -17.65M -758M
Net Debt 67.1M 58.06M 54.19M 49.75M 93.52M 6.39B 94.95M 636M 249M 3.2B 252M 246M 10.58B 71.68M 62.03M 57.9M 53.15M 99.91M 6.82B 101M 679M 266M 3.42B 269M 263M 11.31B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock